CD19 CAR-T cells do not target long-lived autoreactive plasma B cells, nor there is any evidence of its effect on DN2/3 subsets, which have been associated with ADA in SLE, which leaves open the possibility of future relapse (70, 71). This evidence concerns the gene ADA and systemic lupus erythematosus.